Evidence map›Paper›PMID 42784284›Full record

ReviewToxins2026

Botulinum Toxin in Children and Adolescents-A Comprehensive Review of Clinical Applications.

Marko Bašković, Vedrana Nikić Čižmek, Jana Buzuk, Bianka Dujić, Danijela Jurić, Kristina Jurković, Karla Pehar, Sara Vuković

Abstract readReview
In one paragraph

Review in Toxins, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Marko BaškovićSchool of Medicine, Catholic University of Croatia, Ilica 242, 10000 Zagreb, Croatia.ORCID 0000-0003-4218-6184
Vedrana Nikić ČižmekGeneral Hospital "Dr. Ivo Pedišić", Ulica Josipa Jurja Strossmayera 59, 44000 Sisak, Croatia.
Jana BuzukSchool of Medicine, Catholic University of Croatia, Ilica 242, 10000 Zagreb, Croatia.
Bianka DujićSchool of Medicine, Catholic University of Croatia, Ilica 242, 10000 Zagreb, Croatia.
Danijela JurićSchool of Medicine, Catholic University of Croatia, Ilica 242, 10000 Zagreb, Croatia.
Kristina JurkovićSchool of Medicine, Catholic University of Croatia, Ilica 242, 10000 Zagreb, Croatia.
Karla PeharSchool of Medicine, Catholic University of Croatia, Ilica 242, 10000 Zagreb, Croatia.
Sara VukovićSchool of Medicine, Catholic University of Croatia, Ilica 242, 10000 Zagreb, Croatia.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Botulinum toxin, once known only as the cause of botulism, has become a versatile therapeutic agent whose use in children now extends across many medical and surgical specialties. This narrative review synthesises the clinical use of botulinum toxin in patients up to eighteen years of age. We describe its pharmacology, the non-interchangeable commercial preparations, and the weight-based dosing and safety principles specific to childhood, then examine its applications by organ system. Gastrointestinal uses include functional constipation and internal anal sphincter achalasia, persistent obstruction after surgery for Hirschsprung disease, anal fissure, and achalasia. Urological uses centre on neurogenic and idiopathic detrusor overactivity and on sphincter-directed injection for dysfunctional voiding. Neurological uses are dominated by cerebral palsy spasticity and, on considerably weaker evidence, dystonia, while head and neck uses include sialorrhoea, congenital muscular torticollis, and strabismus. We also address neonatal brachial plexus palsy together with hyperhidrosis and aesthetic use in adolescents. The evidence supporting these uses is markedly uneven. Randomised controlled trials exist for only a small number of paediatric indications, chiefly spasticity in cerebral palsy, neurogenic detrusor overactivity, and chronic sialorrhoea, whereas most remaining applications rest on observational cohorts, small case series, or extrapolation from adult practice, and we grade the certainty of evidence separately for every indication. Only a few indications are formally approved, and most remain off-label, though increasingly supported. Botulinum toxin is a reversible and generally safe adjunct, but rigorous paediatric trials are still needed.

Indexed as

Botulinum ToxinsNeuromuscular AgentsAdolescentCerebral PalsyChildChild, PreschoolHumansBotulinum ToxinsNeuromuscular Agentsachalasiaadolescentsbotulinum toxincerebral palsychildrenneurogenic bladderpaediatric surgerysialorrhoeaspasticity

Identifiers

PMID42784284
PMCPMC13611330

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.